So, RSI is about to hit 40 level. Lets see if the price bounces off. price dropped almost 80% after a huge run up.
There is still a gap to fill at ~1.81 and ~1.20
There is still a gap to fill at ~1.81 and ~1.20
Comment:
Indecision...
Indecision...
Comment:
Possibly a QM pattern forming on the 15M
+
Trading near a demand area
+
Bullish divergence
Possibly a QM pattern forming on the 15M
+
Trading near a demand area
+
Bullish divergence
Comment:
Comment:
Ok, so the QM pattern didn't work out. I believe the drop is caused due to stop hunting. The gap at 1.84 is filled now.
Comment:
Price went down 35 cents since first post. Still no update on research. I'll keep an eye on this for the last 4 trading days this month. I will cancel this potential trade if no update or news is provided by the end of the month as this might bleed down without any news.
Comment:
I think the PR released this morning should be sufficient enough to hold this price level. Would be nice to here an update on the oncology part. I believe ovarian cancer trial update is due this month.
AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic
OCALA, FL / ACCESSWIRE / March 26, 2020 / AIM ImmunoTech (NYSE American:AIM) today announced that it is actively seeking investigators and sites for clinical testing of Ampligen as a protective prophylaxis and an early-onset treatment for COVID-19, the disease caused by the SARS-CoV-2 coronavirus.
The company is targeting the United States, Europe, Asia and Argentina for its clinical trials and, as necessary steps before clinical trials could begin, the company is in the process of soliciting one or more sites and qualified principal investigators in one or more countries. Protocols for potential clinical trial are in the final stages of development. AIM intends, as a next step, to as rapidly as possible seek Institutional Review Board approvals and governmental authorizations to commence the clinical trials of Ampligen as both a protective prophylaxis and an early-onset therapy.
AIM has reached several significant COVID-19 milestones over the past two months:
AIM filed provisional patent applications to secure the company's intellectual property before seeking domestic and international research partners.
Japan's National Institute of Infectious Diseases (NIID) agreed to experiment with Ampligen as a potential treatment for COVID-19. The testing and research will be conducted by laboratories at the NIID and the University of Tokyo. AIM will report immediately upon receipt of results.
AIM engaged ChinaGoAbroad (CGA) to facilitate pre-clinical and clinical trials of Ampligen in the People's Republic of China (PRC).
AIM is in discussions with GP-Pharm in Argentina to advance Ampligen for potential use against COVID-19. Ampligen is an approved drug in Argentina for use against myalgic encephalomyelitis/chronic fatigue syndrome.
AIM is in discussions with myTomorrows and Erasmus MC, Rotterdam - where Ampligen was recently used to treat pancreatic cancer patients - to explore expedited pre-clinical and clinical trials of Ampligen.
AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic
OCALA, FL / ACCESSWIRE / March 26, 2020 / AIM ImmunoTech (NYSE American:AIM) today announced that it is actively seeking investigators and sites for clinical testing of Ampligen as a protective prophylaxis and an early-onset treatment for COVID-19, the disease caused by the SARS-CoV-2 coronavirus.
The company is targeting the United States, Europe, Asia and Argentina for its clinical trials and, as necessary steps before clinical trials could begin, the company is in the process of soliciting one or more sites and qualified principal investigators in one or more countries. Protocols for potential clinical trial are in the final stages of development. AIM intends, as a next step, to as rapidly as possible seek Institutional Review Board approvals and governmental authorizations to commence the clinical trials of Ampligen as both a protective prophylaxis and an early-onset therapy.
AIM has reached several significant COVID-19 milestones over the past two months:
AIM filed provisional patent applications to secure the company's intellectual property before seeking domestic and international research partners.
Japan's National Institute of Infectious Diseases (NIID) agreed to experiment with Ampligen as a potential treatment for COVID-19. The testing and research will be conducted by laboratories at the NIID and the University of Tokyo. AIM will report immediately upon receipt of results.
AIM engaged ChinaGoAbroad (CGA) to facilitate pre-clinical and clinical trials of Ampligen in the People's Republic of China (PRC).
AIM is in discussions with GP-Pharm in Argentina to advance Ampligen for potential use against COVID-19. Ampligen is an approved drug in Argentina for use against myalgic encephalomyelitis/chronic fatigue syndrome.
AIM is in discussions with myTomorrows and Erasmus MC, Rotterdam - where Ampligen was recently used to treat pancreatic cancer patients - to explore expedited pre-clinical and clinical trials of Ampligen.
Comment:
I guess we stay in
Trade closed manually:
Closed my position manually and took a small profit. Will get back in if the price drops below 2.50
Divergence near RSI 40 forming?